Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

NIH grants funding to Bionovo for obesity and metabolic syndrome study

Sep. 3, 2010

Halozyme begins phase II trials of PH-20 in type 1 and type 2 diabetes

Sep. 3, 2010

FDA approves Omnitrope for idiopathic short stature

Sep. 3, 2010

New GHRH receptor antagonists disclosed by sanofi-aventis

Sep. 3, 2010

Alipogene tiparvovec shows safety and efficacy in subjects with LPL deficiency / News in Context

Sep. 3, 2010

Biodel changes name of insulin formulation from VIAject to Linjeta

Sep. 2, 2010

Search for novel GPR119 receptor agonists yields AS-1669058

Sep. 2, 2010

New GHS-R antagonists claimed by sanofi-aventis

Sep. 1, 2010

FDA grants orphan drug designation to BMN-701 for Pompe's disease

Sep. 1, 2010

FDA approves Bionovo's CMC plan for Menerba

Aug. 31, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...